CSIMarket
 


Nuvation Bio Inc   (NUVB)
Other Ticker:  
 

Nuvation Bio Inc 's Tangible Leverage Ratio

NUVB's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Despite a net increase in borrowings by 14.92%, Nuvation Bio Inc managed to enhance Tangible Leverage Ratio in the third quarter 2023 to 0.03, falling below the company's typical Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 5 other companies have achieved lower Tangible Leverage Ratio than Nuvation Bio Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 18 to 29 .

Explain Tangible Leverage Ratio?
What is NUVB Market Share?
What are NUVB´s Total Liabilities?


NUVB Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -8.44 % -9.88 % -11.4 % -12.19 % -13.18 %
Y / Y Total Liabilities Change 3.92 % -37.06 % -43.4 % -43.41 % -34.73 %
Tangible Leverage Ratio MRQ 0.03 0.03 0.02 0.03 0.03
NUVB's Total Ranking # 29 # 18 # 23 # 39 # 35
Seq. Tangible Equity Change -2.09 % -2.56 % -2.14 % -1.93 % -3.63 %
Seq. Total Liabilities Change 14.92 % 4.95 % -6.32 % -8.03 % -30.4 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 6
Healthcare Sector # 9
Overall Market # 29


Tangible Leverage Ratio Statistics
High Average Low
27.98 2.36 0.02
(Dec 31 2020)   (Mar 31 2023)




Financial Statements
Nuvation Bio Inc 's Tangible Equity $ 612 Millions Visit NUVB's Balance sheet
Nuvation Bio Inc 's Total Liabilities $ 19 Millions Visit NUVB's Balance sheet
Source of NUVB's Sales Visit NUVB's Sales by Geography


Cumulative Nuvation Bio Inc 's Tangible Leverage Ratio

NUVB's Tangible Leverage Ratio for the trailling 12 Months

NUVB Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -8.44 % -9.88 % -11.4 % -12.19 % -13.18 %
Y / Y Total Liabilities TTM Growth 3.92 % -37.06 % -43.4 % -43.41 % -34.73 %
Tangible Leverage Ratio TTM 0.03 0.03 0.03 0.03 0.04
Total Ranking TTM # 28 # 1 # 2 # 10 # 2
Seq. Tangible Equity TTM Growth -2.09 % -2.56 % -2.14 % -1.93 % -3.63 %
Seq. Total Liabilities TTM Growth 14.92 % 4.95 % -6.32 % -8.03 % -30.4 %


On the trailing twelve months basis Despite of the net new borrowings of 14.92% during the twelve months period ending in III Quarter 2023 Nuvation Bio Inc has managed to unchanged Tangible Leverage Ratio in the III Quarter 2023 to 0.03, below Nuvation Bio Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 5, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Nuvation Bio Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 1 to 28.

Explain Tangible Leverage Ratio?
What is NUVB Market Share?
What are NUVB´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 6
Healthcare Sector # 9
Within the Market # 28


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
27.98 2.36 0.02
(Dec 31 2020)   (Mar 31 2023)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Histogen Inc   0.09 $ 0.381  Millions$ 4.404  Millions
Relmada Therapeutics Inc   0.08 $ 8.422  Millions$ 100.727  Millions
Kura Oncology Inc   0.08 $ 35.699  Millions$ 429.937  Millions
Prelude Therapeutics Inc  0.08 $ 19.779  Millions$ 238.257  Millions
Chimerix Inc   0.08 $ 16.979  Millions$ 208.303  Millions
Dianthus Therapeutics Inc   0.08 $ 14.081  Millions$ 178.381  Millions
Rallybio Corporation  0.08 $ 9.613  Millions$ 123.581  Millions
Ocuphire Pharma Inc   0.08 $ 3.909  Millions$ 50.282  Millions
Pliant Therapeutics Inc   0.07 $ 37.416  Millions$ 503.048  Millions
Nuvalent Inc   0.07 $ 29.103  Millions$ 395.977  Millions
Artelo Biosciences Inc   0.07 $ 0.921  Millions$ 12.539  Millions
Tyra Biosciences Inc   0.07 $ 16.188  Millions$ 222.170  Millions
Edgewise Therapeutics inc   0.07 $ 20.937  Millions$ 290.427  Millions
Trevi Therapeutics Inc   0.07 $ 6.286  Millions$ 89.610  Millions
Olema Pharmaceuticals inc   0.06 $ 17.665  Millions$ 275.134  Millions
Day One Biopharmaceuticals Inc   0.06 $ 24.552  Millions$ 389.627  Millions
Cadrenal Therapeutics Inc   0.06 $ 0.541  Millions$ 8.746  Millions
Medicinova Inc   0.06 $ 3.266  Millions$ 55.069  Millions
Eqrx Inc   0.06 $ 67.310  Millions$ 1,170.920  Millions
Xenon Pharmaceuticals Inc   0.05 $ 34.501  Millions$ 636.592  Millions
Tenax Therapeutics Inc   0.05 $ 0.602  Millions$ 11.287  Millions
Altimmune inc   0.05 $ 7.351  Millions$ 137.978  Millions
Design Therapeutics Inc   0.05 $ 14.912  Millions$ 284.957  Millions
Eledon Pharmaceuticals Inc   0.05 $ 4.734  Millions$ 91.335  Millions
Terns Pharmaceuticals Inc   0.05 $ 13.262  Millions$ 258.425  Millions
Mineralys Therapeutics Inc   0.05 $ 13.543  Millions$ 264.012  Millions
Sagimet Biosciences inc   0.05 $ 4.947  Millions$ 97.875  Millions
Ideaya Biosciences Inc   0.05 $ 24.893  Millions$ 508.049  Millions
Disc Medicine Inc   0.05 $ 17.523  Millions$ 358.974  Millions
Astria Therapeutics inc   0.05 $ 8.894  Millions$ 184.479  Millions

Date modified: 2023-11-03T16:02:10+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com